Table 1.

Baseline characteristics of patients

Germline and somatic DDR genes
VariableOverall cohort N = 36Mutation absent N = 24 (66.7%)Mutation present N = 12 (33.3%)Pa
Age, y0.002
 Median (range)65.5 (45.1–82.7)66.0 (45.1–82.7)64.6 (45.7–74.8)
Gender0.28
 Male21 (58.3)16 (66.7)5 (41.7)
 Female15 (41.7)8 (33.3)7 (58.3)
Race, N (%)0.72
 Caucasian35 (97.2)24 (100)11 (91.7)
 African American1 (2.8)01 (8.3)
CA 19–9, U/mL0.68
 Normal9 (25.0)5 (20.8)4 (33.3)
 Elevated27 (75.0)19 (79.2)8 (66.7)
Family history of cancer, N (%)1
 No17 (48.6)12 (50.0)5 (45.5)
 Yes18 (51.4)12 (50.0)6 (54.5)
Location of primary tumor (%)0.85
 Head32 (88.9)22 (91.7)10 (83.3)
 Body and Tail4 (11.1)2 (8.3)2 (16.7)
Tobacco use (%)0.28
 No15 (48.7)12 (50.0)3 (25.0)
 Yes21 (58.3)12 (50.0)9 (75.0)
BMI (kg/m2)0.39
 ≤24.918 (50.0)13 (54.2)5 (41.7)
 24.9–29.913 (36.1)9 (37.5)4 (33.3)
 ≥305 (13.9)2 (8.3)3 (25.0)
Jaundice at presentation (%)0.90
 No14 (38.8)10 (41.7)4 (33.3)
 Yes22 (61.1)14 (58.3)8 (66.7)
Diabetes at presentation (%)1
 No23 (63.9)15 (62.5)8 (66.7)
 Yes13 (36.1)9 (37.5)4 (33.3)
Adjuvant gemcitabine, N (%)0.86
 No5 (13.9)4 (16.7)1 (8.3)
 Yes31 (86.1)20 (83.3)11 (91.7)
Pathological T stage, N (%)0.35
 T1 and T24 (11.1)3 (12.5)1 (8.3)
 T332 (88.9)21 (87.5)11 (91.7)
Pathological N stage, N (%)0.39
 N05 (13.9)2 (8.3)3 (25.0)
 N131 (86.1)22 (91.7)9 (75.0)
Surgery, N (%)1
 R0 (Negative margin)29 (80.5)19 (79.2)10 (83.3)
 R1 (Positive margin)7 (19.5)5 (20.8)2 (16.7)
  • Abbreviations: BMI, body mass index; CA, carbohydrate antigen; DDR, DNA damage repair; N, node; N, number; T, tumor.

  • aCalculated by χ2 except t test for age.